PET影像组学用于胶质瘤的精准诊断与治疗监测
本文系统综述PET影像组学技术流程及其在胶质瘤分子亚型预测、复发与治疗相关改变鉴别和预后分层中的应用。研究表明氨基酸示踪剂联合多模态影像组学模型诊断效能显著优于传统参数分析,但当前研究仍面临数据异质性、模型可解释性不足和缺乏临床验证等挑战。
要点
- 氨基酸示踪剂(如18F-FET、11C-MET)联合多模态影像组学模型诊断效能显著优于传统参数分析
- PET影像组学可用于预测胶质瘤IDH突变和MGMT甲基化等分子亚型
- PET影像组学有助于鉴别肿瘤复发与治疗相关改变并进行预后分层
核心结论
- PET影像组学通过定量提取多模态影像特征,为胶质瘤无创分子分型、复发鉴别和预后分层提供了新范式,但数据异质性、模型可解释性不足和缺乏临床验证仍是当前挑战。
研究设计与样本
- 综述,系统总结PET影像组学技术流程(示踪剂选择、图像分割、特征提取和模型构建)及其临床应用。
诊断标准与关键数值
- 氨基酸示踪剂(如18F-FET、11C-MET)联合多模态影像组学模型在诊断效能上显著优于传统参数分析
- PET影像组学用于预测分子亚型(如IDH突变和MGMT甲基化)
- PET影像组学用于鉴别肿瘤复发与治疗相关改变
- PET影像组学用于预后分层
临床应用与阅片要点
- 常规MRI在评估代谢状态和鉴别肿瘤复发方面存在局限
- PET影像组学通过定量提取多模态影像特征(如强度、纹理、动态参数)辅助精准诊断与治疗监测
- 未来需多中心标准化方案、开源算法框架和多组学整合以推动临床转化
局限性
- 数据异质性
- 模型可解释性不足
- 缺乏临床验证
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Glioma, the most common primary intracranial tumor, poses significant challenges to precision diagnosis and treatment due to its heterogeneity and invasiveness. With the introduction of the 2021 WHO classification standard based on molecular biomarkers, the role of imaging in non-invasive subtyping and therapeutic monitoring of gliomas has become increasingly crucial. While conventional MRI shows limitations in assessing metabolic status and differentiating tumor recurrence, positron emission tomography (PET) combined with radiomics and artificial intelligence technologies offers a novel paradigm for precise diagnosis and treatment monitoring through quantitative extraction of multimodal imaging features (e.g., intensity, texture, dynamic parameters). This review systematically summarizes the technical workflow of PET radiomics (including tracer selection, image segmentation, feature extraction, and model construction) and its applications in predicting molecular subtypes (such as IDH mutation and MGMT methylation), distinguishing recurrence from treatment-related changes, and prognostic stratification. Studies demonstrate that amino acid tracers (e.g., 18F-FET, 11C-MET) combined with multimodal radiomics models significantly outperform traditional parametric analysis in diagnostic efficacy. Nevertheless, current research still faces challenges including data heterogeneity, insufficient model interpretability, and lack of clinical validation. Future advancements require multicenter standardized protocols, open-source algorithm frameworks, and multi-omics integration to facilitate the transformative clinical translation of PET radiomics from research to practice.
引用
- Zhou C, Ji P, Gong B, et al. Precision Diagnosis and Treatment Monitoring of Glioma via PET Radiomics. Acad Radiol. 2025. PMID: 40681364. doi:10.1016/j.acra.2025.06.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。